MRK Merck & Co., Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

MRK [NYSE]

Merck & Co., Inc.

Healthcare | Drug Manufacturers - General | USA

statements

Index	DJIA S&P500	P/E	19.46	EPS (ttm)	3.98	Insider Own	0.10%	Shs Outstand	2.53B	Perf Week	-2.80%
Market Cap	195.14B	Forward P/E	12.74	EPS next Y	6.07	Insider Trans	-4.25%	Shs Float	2.52B	Perf Month	0.00%
Income	10.20B	PEG	3.24	EPS next Q	1.05	Inst Own	77.70%	Short Float	0.58%	Perf Quarter	-3.96%
Sales	48.08B	P/S	4.06	EPS this Y	58.90%	Inst Trans	0.23%	Short Ratio	1.38	Perf Half Y	-13.60%
Book/sh	10.35	P/B	7.47	EPS next Y	14.61%	ROA	12.10%	Target Price	93.00	Perf Year	-2.99%
Cash/sh	2.95	P/C	26.26	EPS next 5Y	6.00%	ROE	38.10%	52W Range	65.25 - 92.64	Perf YTD	-14.95%
Dividend	2.44	P/FCF	62.36	EPS past 5Y	-1.10%	ROI	19.20%	52W High	-16.50%	Beta	0.49
Dividend %	3.15%	Quick Ratio	0.90	Sales past 5Y	2.10%	Gross Margin	72.20%	52W Low	18.54%	ATR	1.73
Employees	71000	Current Ratio	1.10	Sales Q/Q	11.50%	Oper. Margin	25.50%	RSI (14)	48.74	Volatility	2.00% 2.11%
Optionable	Yes	Debt/Eq	1.07	EPS Q/Q	10.30%	Profit Margin	21.10%	Rel Volume	0.73	Prev Close	76.73
Shortable	Yes	LT Debt/Eq	0.83	Earnings	Jul 31 BMO	Payout	58.30%	Avg Volume	10.55M	Price	77.35
Recom	2.00	SMA20	0.51%	SMA50	-0.97%	SMA200	-6.05%	Volume	7,739,455	Change	0.81%

Jun-12-20

Downgrade

Wolfe Research

Outperform → Peer Perform

Feb-27-20

Initiated

Barclays

Overweight

$93

Jan-07-20

Initiated

RBC Capital Mkts

Sector Perform

$99

Oct-17-19

Resumed

BofA/Merrill

Neutral

$90

Aug-16-19

Initiated

SVB Leerink

Outperform

Jul-03-19

Initiated

Mizuho

Buy

$97

May-28-19

Initiated

Goldman

Neutral

May-13-19

Upgrade

Atlantic Equities

Neutral → Overweight

Oct-16-18

Reiterated

Citigroup

Buy

$70 → $79

Oct-09-18

Resumed

Guggenheim

Buy

Apr-23-18

Upgrade

Goldman

Neutral → Buy

Apr-17-18

Upgrade

Morgan Stanley

Equal-Weight → Overweight

Apr-05-18

Upgrade

Barclays

Equal Weight → Overweight

$62 → $64

Mar-12-18

Upgrade

Leerink Partners

Mkt Perform → Outperform

Feb-14-18

Reiterated

Leerink Partners

Mkt Perform

$67 → $66

Feb-07-18

Reiterated

Morgan Stanley

Equal-Weight

$60 → $63

Jan-16-18

Upgrade

SunTrust

Hold → Buy

Nov-28-17

Resumed

BofA/Merrill

Buy

$64

Nov-24-17

Reiterated

Deutsche Bank

Hold

$62 → $59

Oct-31-17

Upgrade

Jefferies

Underperform → Hold

Jul-13-20 06:33PM	Roche Forecasted to Be Top Drug Seller in 2026 GuruFocus.com
Jul-10-20 10:21AM	Merck's Keytruda Gets Priority Review for Lymphoma Indication Zacks
Jul-09-20 04:30PM	Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews Business Wire
02:10PM	Coronavirus update: Florida sees deadliest day yet as US cases spike, economy jitters grow Yahoo Finance
11:44AM	Coronavirus vaccine makers to testify before U.S. House committee Reuters
08:53AM	New $1 billion fund aims to steer antibiotic companies in tough market Reuters
08:45AM	New $1 billion fund aims to steer antibiotic companies in tough market Reuters
08:40AM	New $1 bln fund aims to steer antibiotic companies in tough market Reuters
08:13AM	Merck's Keytruda Combo Gets CRL for First-Line Liver Cancer Zacks
07:00AM	Prominent plaintiffs' firms sought government bailout to stay afloat Reuters
06:45AM	FDA Grants Priority Review to Mercks Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Business Wire
Jul-08-20 04:30PM	Merck Announces Appointment of Organon & Co. General Counsel Business Wire
01:21PM	Dow Inc., American Express share losses lead the way, but Dow flat MarketWatch
12:59PM	Coronavirus update: US cases spike above 3M as WHO withdrawal draws more critics Yahoo Finance
11:30AM	Where COVID-19 vaccine trials stand Yahoo Finance Video
11:29AM	Immunomedics: A Solid Cancer Research Play GuruFocus.com
07:38AM	Merck, Eisai to put experimental cancer combination in new clinical trial MarketWatch
07:01AM	FDA declines to approve Merck and Eisai's liver cancer combo therapy Reuters
06:55AM	LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer Business Wire
06:45AM	Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma Business Wire
02:24AM	AstraZeneca-Merck's Lynparza wins EU approval for pancreatic cancer Reuters
02:15AM	AstraZeneca-Merck Lynparza wins EU approval for pancreatic cancer Reuters
Jul-07-20 05:50PM	Merck (MRK) Stock Moves -1.08%: What You Should Know Zacks
06:00AM	U.S. government awards Novavax $1.6 billion for coronavirus vaccine Reuters
Jul-06-20 06:45AM	Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection Business Wire
Jul-03-20 09:24AM	How Many Merck & Co., Inc. (NYSE:MRK) Shares Do Institutions Own? Simply Wall St.
Jul-02-20 05:38PM	Were Hedge Funds Right About Merck & Co., Inc. (MRK)? Insider Monkey
03:23PM	Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses Reuters
01:02PM	Keep an Eye on Royalty Pharma Stock, 2020s Biggest IPO InvestorPlace
12:10PM	Why the Earnings Surprise Streak Could Continue for Merck (MRK) Zacks
08:21AM	The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts Benzinga
02:00AM	Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals Business Wire
Jul-01-20 04:30PM	Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction Business Wire
03:24PM	Dow's 25-point climb highlighted by gains in shares of Pfizer, Walt Disney MarketWatch
10:45AM	Dow jumps 25 points on gains for Pfizer, Walt Disney stocks MarketWatch
06:45AM	Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31 Business Wire
Jun-30-20 11:45AM	Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy? Zacks
10:34AM	Merck Gets FDA Nod for Keytruda Use in Colorectal Cancer Zacks
07:41AM	The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test Benzinga
06:40AM	High volatility is here to stay in 2020. Goldman names 31 stocks to deliver the best returns amid the turbulence MarketWatch
Jun-29-20 04:20PM	FDA Approves Mercks KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer Business Wire
09:36AM	Covid Changed the Definition of Corporate Leadership. Meet Barrons New Top CEOs. Barrons.com
07:47AM	These 6 health-care stocks are buys because they can thrive under either Trump or Biden MarketWatch
Jun-26-20 09:22PM	After Building a Cancer-Drug Franchise, Mercks CEO Is Now Tackling Covid-19 Barrons.com
Jun-25-20 03:26PM	Acquiring Biomarin Would Speed Sanofi Transition to New Therapies GuruFocus.com
08:26AM	The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy Benzinga
Jun-24-20 05:29PM	FDA Approves Mercks KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation Business Wire
06:45AM	Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual Business Wire
Jun-23-20 05:50PM	Merck (MRK) Outpaces Stock Market Gains: What You Should Know Zacks
11:31AM	Merck's Pneumococcal Vaccine Meets Goal in Two Adult Studies Zacks
10:45AM	Merck, Apple Inc. share gains contribute to Dow's nearly 150-point jump MarketWatch
09:45AM	JPMorgan Chase, Merck share gains lead Dow's 260-point rally MarketWatch
07:23AM	Merck, BioInvent Enroll First Patient In Solid Tumor Combo Trial SmarterAnalyst
Jun-22-20 12:52PM	How health data is used to target online ads Yahoo Finance Video
09:34AM	Merck Wins Keytruda China Approval; Analyst Applauds First-Mover Advantage SmarterAnalyst
06:45AM	Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults Business Wire
06:30AM	Mercks KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS 10) Business Wire
Jun-19-20 12:02PM	Why Growth Investors will Love These 2 Healthcare Stocks Insider Monkey
08:29AM	Merck Completes Acquisition of Themis Business Wire
Jun-18-20 11:35AM	Merck's Keytruda Gets Accelerated Approval for Solid Tumors Zacks
10:45AM	Dow falls 39 points on losses in shares of UnitedHealth, Cisco MarketWatch
Jun-17-20 05:45PM	Merck (MRK) Dips More Than Broader Markets: What You Should Know Zacks
04:30PM	Merck Animal Health Completes Acquisition of Quantified Ag® Business Wire
02:32PM	Coronavirus update: U.S. death toll edges above 117,000; Oklahoma is one of 9 states that are still setting case records MarketWatch
09:52AM	Stock market tries for 4th straight gain on hope of a V-shaped economic recovery from coronavirus MarketWatch
09:23AM	Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study Zacks
08:41AM	Merck prices four-part bond offering MarketWatch
07:30AM	The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked Benzinga
06:45AM	FDA Approves Second Biomarker-Based Indication for Mercks KEYTRUDA® (pembrolizumab), Regardless of Tumor Type Business Wire
06:30AM	Merck Prices $4.5 Billion Debt Offering Business Wire
Jun-16-20 07:00PM	US Indexes Close Higher Tuesday After Retail Sales Increase 18% GuruFocus.com
03:07PM	Caterpillar, Merck share gains contribute to Dow's 484-point rally MarketWatch
02:06PM	Dow surges 561 points on gains in Caterpillar, Merck shares MarketWatch
01:15PM	Merck and Pfizers SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Business Wire
01:05PM	U.S. appeals court rejects rule requiring drug prices in TV ads Reuters
01:01PM	Caterpillar, Boeing share gains contribute to Dow's 629-point surge MarketWatch
12:43PM	Merck & Co., Inc. -- Moody's assigns A1 rating to Merck's new notes; stable outlook Moody's
12:01PM	Dow's nearly 450-point rally highlighted by gains for shares of Caterpillar, Boeing MarketWatch
10:36AM	U.S. narrows list of promising COVID-19 vaccine candidates to about 7 Reuters
Jun-15-20 05:00PM	UK funds human trials of potential COVID-19 vaccine from Imperial Reuters
12:46PM	Dow drops nearly 125 points on losses in Merck, Home Depot shares MarketWatch
11:46AM	Chevron, Boeing share losses contribute to Dow's 359-point drop MarketWatch
10:46AM	Merck's Gardasil Gets FDA Approval for Head and Neck Cancers Zacks
10:45AM	Dow drops 425 points on losses in shares of Boeing, Chevron MarketWatch
09:36AM	Billions or trillions: The great coronavirus trade-off Yahoo Finance Video
08:00AM	Merck Announces Call for Proposals for Second Cohort of Safer Childbirth Cities, Expanding Maternal Health Support Across US Cities Business Wire
01:48AM	Mercks Gardasil Receives FDA Nod For Expanded Cancer Indications SmarterAnalyst
Jun-14-20 01:52PM	Is Merck A Great Dividend Stock? Motley Fool
Jun-13-20 08:21AM	Billions or trillions: The great coronavirus trade-off Yahoo Finance
06:55AM	Got $1,000? You Might Want To Buy These 2 Coronavirus Stocks Now Motley Fool
Jun-12-20 06:40PM	FDA Approves Mercks GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers Business Wire
02:12PM	Avoid Merck Stock Until Shares Pull Back InvestorPlace
01:48PM	Walmart, Intel share losses lead the way, but Dow flat MarketWatch
10:04AM	Benzinga's Top Upgrades, Downgrades For June 12, 2020 Benzinga
08:54AM	J&J exec: Our coronavirus vaccine is aiming for a 70% success rate in trials Yahoo Finance
Jun-11-20 11:34PM	Japan's PeptiDream to work with Merck in developing COVID-19 therapies Reuters -5.41%
11:37AM	AstraZeneca's R&D Spending Spikes 21% to Industry Best in 2019 GuruFocus.com
Jun-10-20 04:53PM	Dow closes 280 points lower, Nasdaq above 10,000 after Fed says itll keep buying bonds and interest rates near zero MarketWatch
09:09AM	Merck's Keytruda Fails in First-Line Bladder Cancer Study Zacks
05:02AM	Mercks Keytruda Fails To Meet Endpoints In Bladder Cancer Trial SmarterAnalyst

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs for infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products for swine; and dog, cat, and horse vaccines. Additionally, the company offers services and solutions that focus on engagement, clinical, and health analytics. Merck & Co., Inc. has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; Skyhawk Therapeutics, Inc.; Ridgeback Biotherapeutics; Shanghai Junshi Biosciences Co., Ltd.; and FUJIFILM Corporation. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers; and physicians and physician distributors, veterinarians, and animal producers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BRUN LESLIE A	Director	May 07	Option Exercise	0.00	5,000	0	6,948	May 07 04:48 PM
WEEKS WENDELL P	Director	May 07	Option Exercise	0.00	5,000	0	5,100	May 07 04:50 PM
WEEKS WENDELL P	Director	May 07	Sale	76.02	5,000	380,104	100	May 07 04:50 PM
BRUN LESLIE A	Director	May 07	Sale	75.46	5,000	377,300	1,948	May 07 04:48 PM
Clyburn Frank	EVP, Chief Commercial Officer	May 05	Option Exercise	76.86	3,752	288,379	82,611	May 06 05:17 PM
Fleming Michael	SVP Chief Ethics & Com Officer	May 05	Option Exercise	76.86	1,290	99,149	7,304	May 06 05:16 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 05	Option Exercise	76.86	3,283	252,331	29,401	May 06 05:15 PM
Nally Michael	EVP, Chief Marketing Officer	May 05	Option Exercise	76.86	2,345	180,237	12,054	May 06 05:14 PM
Clyburn Frank	EVP, Chief Commercial Officer	May 04	Option Exercise	77.67	1,904	147,884	79,797	May 06 05:17 PM
Fleming Michael	SVP Chief Ethics & Com Officer	May 04	Option Exercise	77.67	692	53,748	6,252	May 06 05:16 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 04	Option Exercise	77.67	1,212	94,136	26,715	May 06 05:15 PM
Zachary Jennifer	EVP, General Counsel	May 04	Option Exercise	77.67	5,772	448,311	9,489	May 06 05:13 PM
Nally Michael	EVP, Chief Marketing Officer	May 04	Option Exercise	77.67	1,298	100,816	10,274	May 06 05:14 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 03	Option Exercise	77.67	875	67,961	25,934	May 05 04:48 PM
Fleming Michael	SVP Chief Ethics & Com Officer	May 03	Option Exercise	77.67	1,541	119,689	6,089	May 05 04:42 PM
Gerberding Julie L.	EVP Strat Comm, GI Pub Policy	Jan 13	Option Exercise	0.00	82,548	0	139,111	Jan 15 05:15 PM
Gerberding Julie L.	EVP Strat Comm, GI Pub Policy	Jan 13	Sale	89.34	102,073	9,118,865	37,038	Jan 15 05:15 PM
Nally Michael	EVP, Chief Marketing Officer	Oct 30	Option Exercise	0.00	2,287	0	6,196	Nov 01 05:07 PM
MIZELL STEVEN	EVP, Chief HR Officer	Oct 30	Option Exercise	0.00	4,574	0	4,574	Nov 01 05:07 PM
Clyburn Frank	EVP, Chief Commercial Officer	Oct 30	Option Exercise	0.00	2,287	0	73,032	Nov 01 05:06 PM
Scholefield James H	EVP,Chief Info&Digital Officer	Oct 30	Option Exercise	0.00	11,436	0	11,436	Nov 01 05:04 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 09	Option Exercise	0.00	6,427	0	77,951	Aug 12 05:13 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 09	Sale	85.09	6,427	546,850	71,524	Aug 12 05:13 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 08	Option Exercise	0.00	31,699	0	103,223	Aug 12 05:13 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 08	Sale	85.01	31,699	2,694,789	71,524	Aug 12 05:13 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience